Skip to main content

SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on May 2, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in patients with type 2 diabetes (T2D) and stage 5 chronic kidney disease (CKD), according to a study published online April 30 in the Annals of Internal Medicine.

Fu-Shun Yen, M.D., from Dr. Yen's Clinic in Taoyuan, Taiwan, and colleagues used the Taiwan National Health Insurance Research Database to identify 23,854 SGLT2i users and 23,892 SGLT2i nonusers with T2D and stage 5 CKD (from May 1, 2016, to Oct. 31, 2021).

The researchers found that compared with no SGLT2i use, SGLT2i use was associated with lower risks for dialysis (hazard ratio [HR], 0.34; 95 percent confidence interval [CI], 0.27 to 0.43), hospitalization for heart failure (HR, 0.80; 95 percent CI, 0.73 to 0.86), acute myocardial infarction (HR, 0.61; 95 percent CI, 0.52 to 0.73), diabetic ketoacidosis (HR, 0.78; 95 percent CI, 0.71 to 0.85), and acute kidney injury (HR, 0.80; 95 percent CI, 0.70 to 0.90). No differences were seen for the risk for all-cause mortality (HR, 1.11; 95 percent CI, 0.99 to 1.24). A lower risk for long-term dialysis was also seen for initiation of an SGLT2i in stage 5 CKD.

"Sodium-glucose cotransporter-2 inhibitors are likely to be a cornerstone in managing patients at different stages of CKD to reduce the risk for dialysis and cardiovascular disease," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

American Diabetes Association, June 21-24

The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world...

Few With Type 2 Diabetes Receive Guideline-Recommended CKD Screening

MONDAY, July 1, 2024 -- Fewer than one-quarter of patients with type 2 diabetes (T2D) receive recommended chronic kidney disease (CKD) screening, according to a study published...

ADA: Bisphenol A Linked to Reduced Peripheral Insulin Sensitivity

THURSDAY, June 27, 2024 -- Bisphenol A (BPA) administration is associated with reduced peripheral insulin sensitivity among healthy adults, according to a study presented at the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.